Paper787451
Tobramycin: an overview.
Neu HC. J Infect Dis, 1976. Cited by 72 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Tobramycin: an overview. Papers, record 787451. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/787451
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Bacteria | Major topic |
| Tobramycin | Major topic |
| Adolescent | |
| Animals | |
| Bacterial Infections | |
| Child | |
| Child, Preschool | |
| Depression, Chemical | |
| Drug Resistance, Microbial | |
| Drug Synergism | |
| Humans | |
| Infant | |
| Kinetics | |
| Male | |
| Protein Biosynthesis | |
| Pseudomonas | |
| Respiratory Tract Infections | |
| Sepsis | |
| Skin Diseases, Infectious | |
| Staphylococcus | |
| Streptococcus | |
| Urinary Tract Infections |
Source PubMed
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40,099,915 | Phenylboronic Acid-Modified Polyethyleneimine: A Glycan-Targeting Anti-Biofilm Polymer for Inhibiting Bacterial Adhesion to Mucin and Enhancing Antibiotic Efficacy. | ACS Appl Mater Interfaces | 2025 | https://conductscience.org/library/papers/40099915 | PubMed |
| 39,731,603 | Application of physiologically based (PBK) modeling to quantify the effect of the antibiotic tobramycin on bile acid levels in human plasma. | Arch Toxicol | 2025 | https://conductscience.org/library/papers/39731603 | PubMed |
| 39,160,204 | Effect of biofilm physical characteristics on their susceptibility to antibiotics: impacts of low-frequency ultrasound. | NPJ Biofilms Microbiomes | 2024 | https://conductscience.org/library/papers/39160204 | PubMed |
| 38,691,668 | Navigating Antibacterial Frontiers: A Panoramic Exploration of Antibacterial Landscapes, Resistance Mechanisms, and Emerging Therapeutic Strategies. | ACS Infect Dis | 2024 | https://conductscience.org/library/papers/38691668 | PubMed |
| 36,340,146 | Drug-Repurposing Approach To Combat Staphylococcus aureus: Biomolecular and Binding Interaction Study. | ACS Omega | 2022 | https://conductscience.org/library/papers/36340146 | PubMed |
| 36,074,177 | In vitro models to detect in vivo bile acid changes induced by antibiotics. | Arch Toxicol | 2022 | https://conductscience.org/library/papers/36074177 | PubMed |
| 34,796,022 | Selective Intestinal Decontamination as a Method for Preventing Infectious Complications (Review). | Sovrem Tekhnologii Med | 2021 | https://conductscience.org/library/papers/34796022 | PubMed |
| 34,435,316 | Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. | Paediatr Drugs | 2021 | https://conductscience.org/library/papers/34435316 | PubMed |
| 31,983,658 | Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). | J Cyst Fibros | 2020 | https://conductscience.org/library/papers/31983658 | PubMed |
| 31,491,963 | Tobramycin Promotes Melanogenesis by Upregulating p38 MAPK Protein Phosphorylation in B16F10 Melanoma Cells. | Antibiotics (Basel) | 2019 | https://conductscience.org/library/papers/31491963 | PubMed |
| 30,805,437 | The road for survival improvement of cystic fibrosis patients in Arab countries. | Int J Pediatr Adolesc Med | 2015 | https://conductscience.org/library/papers/30805437 | PubMed |
| 29,854,560 | Determination of Tobramycin in M9 Medium by LC-MS/MS: Signal Enhancement by Trichloroacetic Acid. | J Anal Methods Chem | 2018 | https://conductscience.org/library/papers/29854560 | PubMed |
| 26,152,473 | Precautionary Practices of Respiratory Therapists and Other Health-Care Practitioners Who Administer Aerosolized Medications. | Respir Care | 2015 | https://conductscience.org/library/papers/26152473 | PubMed |
| 24,836,205 | Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. | Lancet Respir Med | 2014 | https://conductscience.org/library/papers/24836205 | PubMed |
| 23,001,446 | Selective decontamination of the digestive tract: the mechanism of action is control of gut overgrowth. | Intensive Care Med | 2012 | https://conductscience.org/library/papers/23001446 | PubMed |
| 7,399,717 | Optimal antibiotic therapy in bronchopulmonary infections. | Infection | 1980 | https://conductscience.org/library/papers/7399717 | PubMed |
| 7,007,434 | Rapid, reproducible enzyme immunoassay for tobramycin. | J Clin Microbiol | 1981 | https://conductscience.org/library/papers/7007434 | PubMed |
| 6,595,961 | Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6595961 | PubMed |
| 3,311,531 | Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. | Clin Pharmacokinet | 1987 | https://conductscience.org/library/papers/3311531 | PubMed |
| 697,347 | Activity of 5-episisomicin compared with that of other aminoglycosides. | Antimicrob Agents Chemother | 1978 | https://conductscience.org/library/papers/697347 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/787451
GET https://conductscience.org/api/papers/v1/787451/cited_by?page=2